Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation
Evangelos Eleutherakis‐Papaiakovou, Evangelos Terpos, Nikolaos Kanellias, Magdalini Migkou, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Despina Fotiou, Panagiotis Malandrakis, Foteini Theodorakakou, Vasiliki Spiliopoulou, Ioannis V. Kostopoulos, Ourania Tsitsiloni, Panagiotis Tsirigotis, Meletios Α. Dimopoulos, Efstathios Kastritis
Abstract
Autologous stem cell transplantation (ASCT) remains a standard therapy for multiple myeloma (MM) patients. Our study aimed to assess the impact of daratumumab-containing induction on stem cell (SC) mobilization, apheresis and hospitalization. We evaluated 200 newly diagnosed MM patients that were mobilized for SC collection and which received induction with (N = 40) or without daratumumab (N = 160). Dara group patients required more frequent use of plerixafor, larger collection volumes, and had lower SC yield. 87.5% (35/40) of dara group patients achieved the planned yield of ≥ 5 × 10^6 CD34+/kg for at least one transplant compared to 96.2% (154/160) of patients in the non-dara group. Dara group patients had delayed hematopoietic recovery (11 vs 10 days for PMN > 0.5 × 10E9/l), required more transfusions (4 vs 2 plts), prolonged hospitalization (20 vs 18 days), more febrile episodes and prolonged antibiotic administration. Despite daratumumab effect patients finally achieved a successful stem cell collection and proceeded to transplant.